16 Results for "

Anti-CD20

" in MedChemExpress (MCE) Product Catalog:
Products (16)

16 Results for "Anti-CD20" in MCE Product Catalog:

14
14 Cited Publications
Cat. No.: HY-P9913
CAS No.: 174722-31-7
Synonyms: Anti-Human CD20 type I, Chimeric Antibody; HSDB 7455; IDEC-C2B8
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-P9913A
CAS No.: 174722-31-7
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
loading...
    loading...
Cat. No.: HY-P9961
CAS No.: 679818-59-8
Synonyms: GSK1841157; OMB-157

Target:  

CD20

Research Areas:  

Cancer

Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
loading...
    loading...
Cat. No.: HY-P9960
CAS No.: 637334-45-3
Synonyms: 2H7; PRO70769; RG1594

Target:  

CD20

Research Areas:  

Inflammation/Immunology

Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
loading...
    loading...
Cat. No.: HY-P99224
CAS No.: 728917-18-8
Synonyms: IMMU-106; hA20

Target:  

Integrin

Research Areas:  

Cancer

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
loading...
    loading...
Cat. No.: HY-P99308
CAS No.: 1169956-08-4
Synonyms: AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody

Target:  

CD20

Research Areas:  

Cancer

Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
loading...
    loading...
Cat. No.: HY-P99759
CAS No.: 1622189-43-8
Synonyms: IL-15N72D

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

Nogapendekin alfa his tag is an immunostimulant that binds to the IL-2RβγC complex on immune cells. Nogapendekin alfa his tag stimulates the proliferation and activation of natural killer cells and CD8 + T cells, upregulates the expression of granzyme B and perforin, and activates the innate and adaptive immune branches. Nogapendekin alfa his tag forms ALT-803 with IL-15RαSuFc; this complex has an extended biological half-life, improved biodistribution and retention in lymphoid tissues, enhances natural killer cell-mediated rituximab-dependent cellular cytotoxicity, and reduces tumor burden and improves survival when combined with anti-CD20 monoclonal antibody therapy. Nogapendekin alfa his tag can be used in the research of non-Hodgkin's lymphoma .
loading...
    loading...
Cat. No.: HY-P991547
CAS No.: 922534-56-3

Target:  

CD20 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies .
loading...
    loading...
Cat. No.: HY-P99952
CAS No.: 2249927-04-4
Synonyms: SCT400
Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ monoclonal antibody. As an immunomodulator, ripertamab reduces the levels of pathogenic autoantibodies, alleviates immune complex deposition, and blocks the antigen-presenting function of cells. Ripertamab depletes CD20-positive cells. Ripertamab can induce infusion-related reactions, pulmonary toxicity, neutropenia and thrombocytopenia. Ripertamab is applicable to research related to non-Hodgkin's lymphoma, primary membranous nephropathy and idiopathic membranous nephropathy .
loading...
    loading...
Cat. No.: HY-P991225

Target:  

Fc Receptor (FcR) CD20

Research Areas:  

Inflammation/Immunology Cancer

BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
loading...
    loading...
Cat. No.: HY-P990350

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Anti-CD20 Antibody is a humanized antibody expressed in CHO that targets CD20/MS4A1. The Anti-CD20 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD20 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
loading...
    loading...
Cat. No.: HY-P991514

Target:  

CD20

Research Areas:  

Cancer

MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .
loading...
    loading...
Cat. No.: HY-185428
Research Areas:  

Cancer

TRS-005 is an anti-CD20 ADC, formed by conjugating an anti-CD20 monoclonal antibody to MMAE (HY-15162) via a Val-Cit (HY-140014) linker. TRS-005 targets CD20-positive tumor cells and delivers MMAE into cells through receptor-mediated endocytosis. TRS-005 can be used for research on relapsed/refractory B-cell non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma) .
loading...
    loading...
Cat. No.: HY-P992445

Target:  

CD20

Research Areas:  

Cancer

PRO131921 is a humanized IgG1 anti-CD20 antibody, with antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. PRO131921 acts as an anti-tumor agent. PRO131921 can be used for the research of indolent non-Hodgkin lymphoma and relapsed and refractory indolent lymphoma .
loading...
    loading...
Cat. No.: HY-P991904

Target:  

CD20

Research Areas:  

Cancer

TG20 is an anti-CD20 monoclonal antibody that binds to a specific discontinuous epitope on CD20 with a Kd of 10–20 nM. TG20 exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). TG20 also enhances complement-dependent cytotoxicity (CDC) activity. TG20 can be used in research on B-cell lymphomas .
loading...
    loading...
Cat. No.: HY-P991902

Target:  

CD20

Research Areas:  

Cancer

NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a Kd of 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .
loading...
    loading...
  • 1